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(sterrtand arterial)surface:Effect of stent surface on ST was studied in a
porcine exffacorporeal A-V ehunt (A-V) (n = 4 pigs) at a shear rate of 1500
s-’ for20mins. Rough surface slotted-tube stentawere modified by polishing
(n= 10) or polyethylene oxide (antiplatelet coating) (n= 6). ST was reduced
by 91 and 88%, respectively (p -=0.001). The effect of vascular injury was
evaluated by implanting 3 mm slotted-tube stents in pig coronaty arteries (n =
12 pigs, 24 stents). Animals wera sutvived for 6 days and ST was quantified
by maasuring thrombus weight. Underlying vascular injury was gradad as
follows: G1-no disruption of Internal elastic Iamlna (lEL), G2-disruption of IEL
but preeenred external elastic Iamina, G3disruptlon of EEL, G4-penetration
of adventitia by stent atruts. ST directly correlated with vascular injury score
(Speerman’s R = 0.9). Effect of Rfreology; Unpolished stenta wara exposed
in A-V (n = 3 pigs, 15 stents) at shear rate of 500, 1000and 2000s-1. STWSS
3 * 1,8 + 19and 16+39 mg, respectively (gp <0.005 vs 500s-1). Effecrs
ofsysternlccoagulationstatus:Effects of antiplatelet agents clopldogrel (C)
(10 mgkg iv, 6 pigs, 18 stanta) and 7E3 antibody (0.8 mg/kg, iv, 5 dogs, 19
stems were studied In A-V. Bleeding time increased (2 + 1 vs 6 ~ 2 min. for
C; 3 & 1 vs 24 + 3 min. for 7E3: p z 0.05) and ST decreased by 85% and
95%, respectively (p c 0.001). CorIckrsiorzLocal (stent and arterial) surface,
rheology (shear), and systemic thrombotic statua interplay to affeci stent
thrombosis. These mechanistic insights should reconsidered for developing
stent designs and deployment technique.
l_6ZZ6j TiclopidineWhhoutCoumadinlsEno.ghForthe
Preventionof StentThromboeleAfterElecttve
IntracoronaryPalmaz-SchatzStentImplantation-
Resultsof NoPAINtrial
S.Saito, M. Nobuyoshi, K. Oohata, for the NoPAIN Study Group. Shonan
KamakuraGeneralHospital,Kamakura,Japan
To test the effectiveness of ticlopidine in the prevention of atent !hromboais
after elective intraooronary Palmaz-Schatz (P-S) stent implantation without
intrecoronary ultrasound (ICUS) guidanca, wa conductad NoPAIN (Nippon
Prospective Multioenter Randomized Study about Anticoaguiation Therapy
after Intraooronary P-S Stent Implantation) trial. Total of 234 patients were
assigned at random to aither groupC in which the anticoaguiation therapy
with ooumadin and heparin was done or groupTin which the post-stenting
regimen contained 200 mg a day of ticlopidine without coumadin.
Grmn C GrounT P
No.of patients 116 116
Age 63& 10 62& TO NS
Male gender 7s”/0 75% NS
Stentthrombosis 2 (1.7%) none NS
Q-Ml 2 (1.7%) none NS
CABG 1 (0.9%) none NS
Major bleeding none none NS
Liverdysfunction none none NS
Leukocytopenia nona none NS
Death none none NS
Thue we mncluda that 200 mg of ticlopidine without coumadin ia anough
for peat-stenting regimen after alecfive P-S atent implantation without ICUS
guidance.
D92721 Multilink’”Stenting,a ‘Minimalist’ApproschUsingAapirinAlone-No Ticlopidine,NoCoumadin,No
IVUSandNoQCA
A.L. Calver, K.D. Dawkins, G.A. Haywood, H.H. Gray,J.M. Morgan,
LA. Simpeon. WessexCardiacUnit,Southampton,UK
Developments in technology need to be judged againet clinical efficacy and
cast-benefit. In order to determine the outcome of a ‘minimalist’ approach to
intre-ooronary stanting we have studied prospectively 98 patiants receiving
134 Multilink”’ stents to 120 Coronaw artery Ieeions. Pta were pre-treated
with Aspirin 300 mgs, given procedural Heparfn (l&15,000 IU) and post-
procadure Aepitin alone. Moderate post-implant high preseure dilatation to
14 (SD+ 1.6) atmoe. was used in all @swith no IVUSor QCA in the catheter
lab&atory.
Avarage age of the group was 60 (range 37-82) yre, 76 (76%) male.
Veseele: LAD 54, RCA 37, Cx 37, diagonal 1, intermediate 1, vein grafts 6.
Lesion typea: A 38, BI 53, BZ 21, C 8.24 pta (25%) had unstable-angina.
Indications for stanting: elective 94 (78%), cub-optimal reeult 24 (20%),
bail-out 2 (2%). Poet procedural length of stay 1.8 (SD + 1.8) days. ln-
hoepifal oomplioatione: Death O, CABG O, AMI (non-Q) 1 (l%). Subacuta
stent thrombosis occurred in no pts. Follow-up was available for 92/98 pts
(94%) mean 74 (range 6-271) days, during which time there were no major
cardiac eventa (death, CABG, AMI, m-intervention).
Cone/usior?s;1. Coronary intervention with the Multilink’” stent ia safe and
effective using a eimple and cost effective ‘minimalist’ approach. 2. In this
study, there were no adverse events (eg stent thrombosis) as a result of
adopting this etrategy.
m92722 CombinedAntlplateletTherapyWithoutAntlcoaguistlonAfterStentImplantation:The
TiclopldineAspirinStentEvaluation(TASTE)Study
J.-M. Lablanche, J.-L. Bonnet, G. Grollier, N. Danchin, M. Bedosaa,
A. Vahanian, E.P.McFadden, C. Bauters, E. Van Belle, M.E. Bertrand.
UniveralfyofLil/e,France
The major limitations of coronaty stent implantation, subacute occlueion and
peripheral vascular complications, have been markedly reduced bytheuaeof
combined antiplatelet therapy as an alternative to classical anticoagulation.
We repwfthecurrent results of the TASTE registry,a prospective multicenter
Frenchetudytoevaluate the efficacy of a combination of2antipiatelet agenta,
ticlopidine 500 mg and aspirin 180 mg daily with heparin administration
aefor oonventionai angioplasty (parprocedural and until sheath removal),
aftar stent implantation. From November 1993 to December 1995, 1404
stents ware implanted in 1064 consecutive patients (1136 veesels) for failed
angioplasfy (n = 140), a suboptimal result (n = 706), or electively (n =
217). Stents usad were Palmaz-Schatz (73%), Wiktor (22%), AVE (3%),
Gianturco-Roubin (2%). The maximal inflation preseure used was > 14
atmospheres in 43% (range 4 to 22). Balloon diameter was 2.5 mm (10%),
3.0 mm (50%), 3.5 mm or greater (40%). Sheath size was 6 French in
42%, and 8 French in 43%. We present tha procedural, in-hoepital, and
early clinical follow-up results. Coronary events related or possibly related to
stent implantation occurrad in 5.770 of patients with bailout stenta, 2.1% of
patients with .St8ntsfOrSubOptimalreSUltS,and in 0.9% Of8k?CfivelyStWrteCf
patients. In a multivariata analysie, factors ralated to etent occlusion were
stent implant forpost-procedural occlusion outside tha cath lab (p = 0.0001),
residual dissection or hazinees after stenting (p = 0.002), and placement of
> 1 stent (p = 0.03). Serious vascular complications (requiring aurgery or
transfusion) occurred in 1.0%. Neither stent thromboaia nor serioua bleeding
occurred affar alective stenting. Mean hospital stay deoreaeed from 6.2 daya
to 3.4 daye.
A combination of 2 antiplatelet agents can be employed in tha vaet
majority of patients after coronary stent implantation. Subacute occlueion
ratee and bleeding complication compare favorably with those reported
ueing conventional therapy and the duration of hoapitslieation is reduced.
/927-231 ClinicalandAngiographicFoUow-upof Stenting
WithoutAnticoagulation:TheTiclopidineAapirin
StentEvaluation(TASTE)Study
J.-M. Lablanche, N. Danchin, J.-L. Bonnat, C. Lecleroq, G. Grollier,
E.P.McFadden, E. Van Belle, C. Bauters, M.E. Bertrand. UniveraityofLi//e,
France
Stent implantation without antiooagulation is now atandard management in
many countries. In a prospective multicentre Franch study, we have followed
patients with stent implantation, managed with ticlopidine500 mg and aspirin
160 mg daily,without oral anticoagulation. We repcrrftheclinical (n=606) and
angiographic (n= 510) follow-up in patients who underwent successful etent
implantation (TIMI grada 3flowafterstenting without in-hospital complication)
and who were treated by protocol (ticlopidine 500 mg daily and aspirin).
Stents were implanted predominantly for a auboptimal result (66%) or aa
bailout (13%).
In the 7 months after hospital discharge 6 (l%) deaths occurred, 4 unre-
lated to stenting (Ieukamia, suicide, stroke) and 5 (0.9%) myocardial infarc-
tions occurred; 4 (0.7%) in non-atented vessals and 1 (0.2%) in a etented
veseel 10 weeka after etenting. CABG that included tha stented vessel wae
performed in 12 (2%) patients and for disaaee in nonstented vesasis in
a further 12 (2%) patianta. Further PTCA was performed in 183 (30.2%)
patients; in 125 (20.6%) patients for restenosis, and in 56 (9.6%) patients
at a non-stented site. Ticlopidine-related neutropenia occurred in 1.4% of
patients, allergic reactions in 2.5% of patients, thrombooytopenia in 0.6%,
and hepatitis in 0.80A.Atangiographic follow-up, restenosis (> 50% stenosis
vieually) was preeent in 37.4% of stents including 1.7% total ocoluaions.
Stanting managed by antiplatelet therapy alone was associated with a
low rate of eerious complications (death, Ml). The relatively high restenoaie
rate may reflect the predominance of nonelective indications.
